Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|November 1, 2000
Supplements and Featured Publications
- Clinical and Economic Impact of Low-Molecular Weight Heparins in Managed Care
- Volume 6
- Issue 20 Suppl
Selected Abstracts
Advertisement
Articles in this issue
almost 26 years ago
Participating Facultyalmost 26 years ago
Introductionalmost 26 years ago
Overview of Enoxaparin in the Treatment of DVTalmost 26 years ago
DVT and Pulmonary Embolism in the Perioperative Patientalmost 26 years ago
CME/CPE Article: Economics of Low-Molecular Weight Heparinsalmost 26 years ago
CME/CPE QuizAdvertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5